Bolt Biotherapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 20 million compared to USD 27.16 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.73 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7929 USD | -3.90% | -37.07% | -29.21% |
15/05 | Top Midday Decliners | MT |
15/05 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.21% | 30.23M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- BOLT Stock
- News Bolt Biotherapeutics, Inc.
- Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022